- Home
- VIGL
as 07-26-2024 4:00pm EST
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 159.4M | IPO Year: | 2022 |
| Target Price: | $16.75 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.47 - $9.24 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Vigil Neuroscience Inc. (VIGL)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Magovcevic-Liebisch Ivana | VIGL | President and CEO | Nov 20 '23 | Buy | $3.75 | 4,000 | $15,000.00 | 207,687 | SEC Form 4 |
Latest Vigil Neuroscience Inc. News
VIGL Breaking Stock News: Dive into VIGL Ticker-Specific Updates for Smart Investing
Benzinga
2 days ago
Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease Bimarker
GlobeNewswire
3 days ago
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
MT Newswires
7 days ago
HC Wainwright Cuts Price Target on Vigil Neuroscience to $17 From $24, Maintains Buy Rating
GlobeNewswire
8 days ago
Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference
GlobeNewswire
9 days ago
Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP
Insider Monkey
a month ago
Vigil Neuroscience, Inc. (VIGL): Is This the Best Biotech Penny Stock to Buy Now?
MT Newswires
a month ago
Wedbush Adjusts Price Target on Vigil Neuroscience to $23 From $22 on Heels of Sanofi Investment, Maintains Outperform Rating
MT Newswires
a month ago
Top Premarket Gainers
Compare VIGL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VIGL Vigil Neuroscience Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.